(HealthDay News) — A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show. Aucatzyl (obecabtagene autoleucel) worked on more than three-quarters (76%) of patients with B-cell acute lymphoblastic leukemia (ALL), and more than half (55%) went into remission, according to results published recently in the New England Journal of Medicine. […]